A randomized study of alglucosidase alfa in late-onset Pompe's disease

New England Journal of Medicine

Volumn 362, Issue 15, 2010, Pages 1396-1406

  Van Der Ploeg, Ans T ^a   Clemens, Paula R ^b   Corzo, Deyanira ^c   Escolar, Diana M ^d   Florence, Julaine ^e   Groeneveld, Geert Jan ^c   Herson, Serge ^f   Kishnani, Priya S ^g   Laforet, Pascal ^f   Lake, Stephen L ^c   Lange, Dale J ^h   Leshner, Robert T ^d   Mayhew, Jill E ^d   Morgan, Claire ^c   Nozaki, Kenkichi ^e   Park, Dorothy J ⁱ   Pestronk, Alan ^e   Rosenbloom, Barry ⁱ   Skrinar, Alison ^c   Van Capelle, Carine I ^a   Van Der Beek, Nadine A ^a   Wasserstein, Melissa ^h   Zivkovic, Sasa A ^b   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c GENZYME CORPORATION   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ Tower Hematology Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ADOLESCENT; ADULT; AGED; ALLERGY; ANAPHYLAXIS; ANEURYSM; ANGIONEUROTIC EDEMA; ARTERY THROMBOSIS; ARTICLE; ARTIFICIAL VENTILATION; BLOOD PRESSURE; BRAIN ISCHEMIA; CHILD; CLINICAL TRIAL; DEHYDRATION; DIVERTICULITIS; DRUG INFUSION; EUROPE; FALLING; FEMALE; FLUSHING; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; GLYCOGEN STORAGE DISEASE TYPE 2; HEADACHE; HEALTH CENTER; HUMAN; HUMERUS FRACTURE; HYPERHIDROSIS; HYPERSENSITIVITY; ISCHEMIC HEART DISEASE; LUNG FUNCTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PANNICULITIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SKIN TOXICITY; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; THROAT DISEASE; TONGUE EDEMA; UNITED STATES; URTICARIA; VOMITING; WALKING;

EID: 77950963839     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0909859     Document Type: Article

References (34)

1. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008;372:1342-1353
2. Chen YT, Amalfitano A. Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol Med Today 2000;6:245-251 (Pubitemid 30394911)
3. van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-340 (Pubitemid 36951395)
4. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-676 (Pubitemid 43776899)
5. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: Scriver CK, Beaudet AL, Sly WS, et al., eds. The metabolic & molecular bases of inherited disease. 8th ed. Vol. 3. New York: McGraw-Hill, 2001:3389-3420
6. Laforêt P, Nicolino M, Eymard PB, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000;55:1122-1128
7. Hagemans ML, Winkel LP, Van Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128:671-677
8. Müller-Felber W, Horvath R, Gempel K, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007;17:698-706. (Pubitemid 47362681)
9. Wokke JH, Escolar DM, Pestronk A, et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008;38:1236-1245
10. Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004;55:495-502. (Pubitemid 38391966)
11. Mellies U, Stehling F, Dohna-Schwake C, Ragette R, Teschler H, Voit T. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology 2005;64:1465-1467 (Pubitemid 40570526)
12. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109.
13. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397-398 (Pubitemid 30487498)
14. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138
15. Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009;11:210-219
16. Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009;66:329-355
17. van Capelle CI, Winkel LP, Hagemans ML, et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 2008;18:447-452
18. Angelini C, Semplicini C, Tonin P, et al. Progress in enzyme replacement therapy in glycogen storage disease type II. Ther Adv Neurol Disord 2009;2:143-153
19. Strothotte S, Strigl-Pill N, Grunert B, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2009;257:91-97
20. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
21. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117
22. American Thoracic Society/European Respiratory Society. ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 2002;166:518-624.
23. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187
24. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969;99:696-702.
25. The National Isometric Muscle Strength (NIMS) Database Consortium. Muscular weakness assessment: use of normal isometric strength data. Arch Phys Med Rehabil 1996;77:1251-1255
26. Mayhew JE, Florence JM, Mayhew TP, et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 2007;35:36-42.
27. Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User's manual for the SF-36v2 health survey. 2nd ed. Lincoln, RI: QualityMetric Incorporated, 2007.
28. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006;149:89-97. (Pubitemid 44081924)
29. Wang J, Lozier J, Johnson G, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 2008;26:901-908
30. Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. DIA Journal 2000;35:1095-1112
31. Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 2005;64:2139-2141
32. Hagemans ML, Janssens AC, Winkel LP, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 2004;63:1688-1692
33. Van der Beek NA, Hagemans ML, Reuser AJ, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 2009;19:113-117
34. Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006;86:1208-1220 (Pubitemid 44789911)